Journal of Oncology Translational Research

Immune modulation in breast cancer

Abstract

Lamiss Mohamed

Background: Breast cancer is one among the foremost common malignancies in women worldwide, and one among the leading causes of cancer-related death.
The decimal prognosis of breast cancer subtypes including triple negative breast cancer has been linked with immune response. So our aim to evaluate the
programmed death and tumor infiltrating lymphocytes in prognosis of breast cancer subtypes including triple negative breast cancer subtypes.
Methods: Systematic review for evaluating the prognostic ability of PD-L1 expression levels in predicting positive clinical outcomes in Breast Cancer. The
outcomes evaluated are going to be Overall Survival, Breast Cancer-specific Survival, Disease-free Survival, Recurrence-free Survival, Positive lymph gland, and
Distant Metastasis.
Discussion: Immunomodulation seems to be a promising strategy in solid tumors. Worldwide, breast cancer is the most common malignancies in women, and
one of the leading causes of cancer death. PD-1 and PD-L1 are key physiologic suppressors of the cytotoxic immune response.